TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37697491

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Oral rinse activated matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Determination of gingival bleeding on brushing (GBoB)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Machine learning classifiers (Random Forest analyses)
Number of subjects: 408
Study: 37697655

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Subclinical diabetes (subclinical DM)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 713
Study: 37697666

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation with hyaluronic acid (20 mL in total) + physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation with hyaluronic acid + physical therapy
Number of subjects: 0
Study: 37697745

Group type: EXPERIMENTAL
Intervention: 10min texting (Group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15min texting (Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10min writing (Group C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15min writing (Group D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (15min talking or watching, Group E)
Number of subjects: 50
Study: 37697811

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BNX)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Methadone maintenance therapy (MMT)
Number of subjects: 268
Study: 37697813

Group type: EXPERIMENTAL
Intervention: Heparin bridging strategy used during edoxaban interruption (178 procedures)
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Edoxaban interruption
Number of subjects: 2089
Study: 37698366

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA
Number of subjects: 12466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12466
Study: 37698430

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 20
Study: 37698443

Group type: EXPERIMENTAL
Intervention: Self-management intervention for COPD (details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not available)
Number of subjects: 0
Study: 37698477

Group type: COMPARATOR
Intervention: Coronary CTA-derived FFR normal results
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Coronary CTA-derived FFR abnormal results
Number of subjects: 900
Study: 37698478

Group type: EXPERIMENTAL
Intervention: High-dose Erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative brain injury scoring by radiologists
Number of subjects: 0
Study: 37698480

Group type: EXPERIMENTAL
Intervention: 4D CT scans
Number of subjects: 150

Group type: COMPARATOR
Intervention: Follow-up of inconclusive group participants
Number of subjects: 150
Study: 37698591

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention in a support group setting via Zoom
Number of subjects: 0
Study: 37698604

Group type: EXPERIMENTAL
Intervention: Uterine massage after vaginal delivery before placental delivery (n: 128)
Number of subjects: 242

Group type: COMPARATOR
Intervention: No uterine massage (Control group, n: 114)
Number of subjects: 242
Study: 37698632

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Durvalumab combined with Gemcitabine and Cisplatin or Carboplatin
Number of subjects: 0
Study: 37698645

Group type: EXPERIMENTAL
Intervention: Anatomic segmentation-based dosimetry
Number of subjects: 209

Group type: COMPARATOR
Intervention: Count threshold-based dosimetry
Number of subjects: 209
Study: 37698662

Group type: EXPERIMENTAL
Intervention: Combination of triamcinolone acetonide (TA) (40 mg) and VISCOAT (sodium chondroitin sulfate 20 mg and sodium hyaluronate 15 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) (40 mg) in the posterior subtenon space
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Suprachoroidal triamcinolone (4 mg/100µl)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 37698660

Group type: EXPERIMENTAL
Intervention: Modified Monthly Regimen (mMR), total dose-5.5 g, with intake of oral GCs after completion of intravenous infusions.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Weekly Regimen (WR), total dose-4.5 g.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Modified Monthly Regimen (mMR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Weekly Regimen (WR)
Number of subjects: 62
Study: 37698745

Group type: EXPERIMENTAL
Intervention: Mobile health exercise intervention (daily steps and resistance training data entered into an app)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mobile health exercise intervention
Number of subjects: 7
Study: 37698774

Group type: EXPERIMENTAL
Intervention: BNT162b2 + SIIV
Number of subjects: 1128

Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 1128

Group type: COMPARATOR
Intervention: SIIV
Number of subjects: 1128
Study: 37698836

Group type: EXPERIMENTAL
Intervention: 120-mg galcanezumab
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: 240-mg galcanezumab
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 37698862

Group type: EXPERIMENTAL
Intervention: Care management intervention for a mean of 120 days after hospital discharge
Number of subjects: 782

Group type: COMPARATOR
Intervention: Usual postdischarge care (Control)
Number of subjects: 782
Study: 37698881

Group type: EXPERIMENTAL
Intervention: Glasdegib (50 mg once daily in 28-day cycles)
Number of subjects: 35
Study: 37698896

Group type: EXPERIMENTAL
Intervention: Foster Care Family Navigator (FCFN) intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (clinical case management services)
Number of subjects: 80
Study: 37698915

Group type: EXPERIMENTAL
Intervention: Better Nights, Better Days (BNBD-NDD) eHealth behavioral intervention delivered to parents (5 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37698922

Group type: EXPERIMENTAL
Intervention: High oxLDL
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Low oxHDL
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Plasma oxHDL levels
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: oxHDL
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Combined Met136 mono-oxidation and Trp132 dioxidation of HDL
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Met136 mono-oxidation
Number of subjects: 306
Study: 37699050

Group type: EXPERIMENTAL
Intervention: E-liquids with 5% free-base nicotine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 25% free-base nicotine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 45% free-base nicotine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 65% free-base nicotine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 85% free-base nicotine
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 20 mg/mL total nicotine concentration
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: E-liquids with 50 mg/mL total nicotine concentration
Number of subjects: 132
Study: 37699064

Group type: EXPERIMENTAL
Intervention: 120 μg RSVPreF3-AS01E (third dose)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Previous 2 doses of RSVPreF3-AS01E
Number of subjects: 122
Study: 37699161

Group type: EXPERIMENTAL
Intervention: START (Startle Adjuvant Rehabilitation Therapy) with 105-dB white noise GO cues during one third of trials
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: START (Startle Adjuvant Rehabilitation Therapy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (77-dB GET READY and GO cues only)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (mild controls)
Number of subjects: 42
Study: 37699162

Group type: EXPERIMENTAL
Intervention: Alpelisib (PIK3CA inhibitor)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Poziotinib (EGFR/HER2 inhibitor)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Nintedanib (FGFR inhibitor)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Abemaciclib (CDK4/6 inhibitor)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Durvalumab ± Tremelimumab (anti-PD-L1/CTLA-4 inhibitor)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Crossover to arm 5 (Durvalumab ± Tremelimumab) after progressive disease in arms 1-4
Number of subjects: 203
Study: 37699237

Group type: EXPERIMENTAL
Intervention: Managing chemotherapy symptoms (e.g., medication, home remedies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipating and mitigating symptoms (e.g., management of symptoms at home, anticipatory guidance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowing when to seek care (e.g., unexpected and unusual symptoms)
Number of subjects: 0
Study: 37699333

Group type: EXPERIMENTAL
Intervention: Pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1.1
Number of subjects: 799
Study: 37699601

Group type: EXPERIMENTAL
Intervention: Scalp-sparing volumetric-modulated arc therapy (SSV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-SSV
Number of subjects: 19
Study: 37699623

Group type: EXPERIMENTAL
Intervention: Implantation of a Reveal Linq device (Medtronic) and percutaneous PFO closure performed 2 months after device implantation.
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Incidence and burden of AF in the 2 months prior to PFO closure and up to 2 years after PFO closure.
Number of subjects: 250
Study: 37699630

Group type: EXPERIMENTAL
Intervention: Intranasal Q-Griffithsin (Q-GRFT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Initial version of SPRAY PAL questionnaire
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Revised version of SPRAY PAL questionnaire
Number of subjects: 40
Study: 37699634

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment (Tislelizumab) starting at Day 8 of radiation (concurrent plan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 treatment (Tislelizumab) starting 2 weeks after completion of radiation (sequential plan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-course radiotherapy plus concurrent capecitabine (control arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (all arms)
Number of subjects: 0
Study: 37699636

Group type: EXPERIMENTAL
Intervention: Oral hydration
Number of subjects: 254

Group type: COMPARATOR
Intervention: Intravenous hydration
Number of subjects: 254
Study: 37699654

Group type: EXPERIMENTAL
Intervention: Otilimab 90 mg
Number of subjects: 3162

Group type: EXPERIMENTAL
Intervention: Otilimab 150 mg
Number of subjects: 3162

Group type: EXPERIMENTAL
Intervention: Otilimab
Number of subjects: 3162

Group type: COMPARATOR
Intervention: Tofacitinib
Number of subjects: 3162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3162
Study: 37699709

Group type: EXPERIMENTAL
Intervention: Single intravenous KPL-404 dose 0.03, 0.3, 1, 3, or 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single subcutaneous KPL-404 dose 1 or 5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 37699719

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 3157

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 3157

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 3157
Study: 37699726

Group type: EXPERIMENTAL
Intervention: AI-CDSS intervention group
Number of subjects: 21689

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 21689
Study: 37699851

Group type: EXPERIMENTAL
Intervention: Letrozole (LZ) 5 mg co-treatment during ovarian stimulation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 37700015

Group type: EXPERIMENTAL
Intervention: Transanal TME (taTME)
Number of subjects: 100
Study: 37700101

Group type: EXPERIMENTAL
Intervention: 3D printed models in addition to standard CT imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CT imaging alone
Number of subjects: 0
Study: 37700239

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37700241

Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 25-100%)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 50-200%)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: STEPWISE app (intervention arm with increases of 100-400%)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Active control group (increase of 5-20%)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Physical fitness, motor- and non-motor function measures
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Dose-response relationship
Number of subjects: 452
Study: 37700245

Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI)
Number of subjects: 258
Study: 37700249

Group type: EXPERIMENTAL
Intervention: High-dose intravenous ascorbic acid (50 mg/kg every 6 h for 96 h)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 37700288

Group type: EXPERIMENTAL
Intervention: Eat, Walk, Sleep (EWS)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: EWS plus medication therapy management (EWS + MTM)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Social services (SS)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 188
Study: 37700317

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 425
Study: 37700334

Group type: EXPERIMENTAL
Intervention: Daily smartphone-based monitoring and treatment including clinical feedback
Number of subjects: 201

Group type: COMPARATOR
Intervention: Daily smartphone-based monitoring without clinical feedback
Number of subjects: 201

Group type: COMPARATOR
Intervention: Daily smartphone-based mood monitoring only
Number of subjects: 201
Study: 37700348

Group type: COMPARATOR
Intervention: PF regimen (cisplatin and 5-fluorouracil)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: DP regimen (docetaxel and cisplatin)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 86
Study: 37700375

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metformin intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 37700443

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide (all doses)
Number of subjects: 0
Study: 37700689

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam (plus metronidazole for cIAI)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Comparator (carbapenems in >97% of patients)
Number of subjects: 813
Study: 37700687

Group type: EXPERIMENTAL
Intervention: Higher fractions of inspired oxygen (FiO2)
Number of subjects: 10385

Group type: COMPARATOR
Intervention: Lower fractions of inspired oxygen (FiO2)
Number of subjects: 10385
Study: 37700695

Group type: EXPERIMENTAL
Intervention: Electrical dry needling
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-invasive multicomponent intervention
Number of subjects: 64
Study: 37700773

Group type: EXPERIMENTAL
Intervention: Transpulmonary pressure-guided PEEP with electrical impedance tomography (EIT)
Number of subjects: 1
Study: 37701088

Group type: EXPERIMENTAL
Intervention: Aspiration of endometrial cavity fluid with diosmin intake
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (conservative management)
Number of subjects: 200
Study: 37701986

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-based combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab monotherapy
Number of subjects: 0
Study: 37702047

Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation (400 mg nitrate in 70 mL beetroot juice)
Number of subjects: 55
Study: 37702079

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 8242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8242
Study: 37702300

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamin C, E, beta-carotene, and zinc)
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Lutein/zeaxanthin
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Zinc
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Multivitamin (including lutein/zeaxanthin)
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 11952

Group type: COMPARATOR
Intervention: Visual Function Questionnaire
Number of subjects: 11952
Study: 37702406

Group type: EXPERIMENTAL
Intervention: Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study: 37702427

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (OA) combined with mechanical bowel preparation (MBP)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 309
Study: 37702442

Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis
Number of subjects: 292

Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 292
Study: 37702453

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine HCl 1.25% (Pilo)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 375
Study: 37702559

Group type: EXPERIMENTAL
Intervention: HCT 25 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 37702588

Group type: EXPERIMENTAL
Intervention: Temsirolimus 25 mg i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Temsirolimus and bevacizumab combination therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 59
Study: 37702912

Group type: EXPERIMENTAL
Intervention: Peer-facilitated, manualized, 7-session group intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 143
Study: 37702920

Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg (intravenous infusion on Day 1)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Sotrovimab 500 mg
Number of subjects: 1057
Study: 37703006

Group type: EXPERIMENTAL
Intervention: Evinacumab, 15 mg/kg, intravenously Q4W
Number of subjects: 96
Study: 37703015

Group type: EXPERIMENTAL
Intervention: Green labels ("choose often")
Number of subjects: 7945

Group type: EXPERIMENTAL
Intervention: Traffic light labels
Number of subjects: 7945

Group type: EXPERIMENTAL
Intervention: Physical activity calorie equivalent labels
Number of subjects: 7945

Group type: EXPERIMENTAL
Intervention: Nutrient warning labels
Number of subjects: 7945

Group type: COMPARATOR
Intervention: Calorie labels only (control)
Number of subjects: 7945
Study: 37703030

Group type: EXPERIMENTAL
Intervention: Acute exercise (60 min at 61% of peak oxygen uptake)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (rest and high-fat meals)
Number of subjects: 20
Study: 37703037

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT) for 1 year (36 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of Care (SOC) psychotherapy (schedule clinically determined) for 1 year
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 100
Study: 37703083

Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor treatment
Number of subjects: 0
Study: 37703082

Group type: EXPERIMENTAL
Intervention: Tele-yoga intervention
Number of subjects: 89
Study: 37703248

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app, including daily practice prompts, mindfulness exercises, virtual counseling, and daily psychological status logs.
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app.
Number of subjects: 670

Group type: COMPARATOR
Intervention: Audio-based standardized mindfulness practice instructions three times per week (control group).
Number of subjects: 670
Study: 37703330

Group type: EXPERIMENTAL
Intervention: Cut-point-free metrics (Intensity Gradient - IG)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Cut-point-free metrics (Average Acceleration - AvAcc)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Cut-point-based metrics (moderate-to-vigorous and vigorous activity)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Reference values for IG and AvAcc
Number of subjects: 530
Study: 37703353

Group type: EXPERIMENTAL
Intervention: mRNA-1283
Number of subjects: 0

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 0
Study: 37703397

Group type: EXPERIMENTAL
Intervention: Open lidocaine administration
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Open capsaicin administration
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hidden lidocaine administration
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hidden capsaicin administration
Number of subjects: 47
Study: 37703482

Group type: EXPERIMENTAL
Intervention: 68 Ga-DOTATATE PET/CT
Number of subjects: 220
Study: 37703506

Group type: EXPERIMENTAL
Intervention: Magrolimab with azacitidine
Number of subjects: 87
Study: 37703513

Group type: EXPERIMENTAL
Intervention: Focus group discussions with parents regarding meals, traditional foods, beverages, physical activity, and screen time.
Number of subjects: 0